
Resultados clínicos do RET Germline M918T Variante patogênica no Carcinoma da Tiróide Medular Hereditária: Revisão Sistemática e Meta-Análise
OncologiaResumo original em inglês
O que aconteceu
Hereditary medullary thyroid carcinoma (hMTC) exhibits substantial clinical heterogeneity according to the underlying germline RET pathogenic variant. Although the germline RET M918T pathogenic variant is associated with aggressive disease, its associations with clinical outcomes have not been comprehensively quantified. We aimed to evaluate the associations between the M918T variant and adverse clinical outcomes in patients with hMTC.
PubMed, Scopus, and Embase were searched from database inception to May 2026 in accordance with PRISMA 2020. Eligible studies compared patients with the germline RET M918T pathogenic variant with those harboring other germline RET pathogenic variants. Random-effects models were used to pool odds ratios (ORs) and 95% confidence intervals (CIs) for lymph node metastasis, metastatic disease, advanced-stage disease, and mortality. Risk of bias was assessed using the Quality in Prognosis Studies tool. The protocol was prospectively registered in PROSPERO (CRD420261377120).
O que encontraram
Nine cohort studies involving 1485 participants were included, with outcome-specific sample sizes varying. Three studies had a low overall risk of bias and six had a moderate risk. The M918T variant was associated with increased odds of lymph node metastasis (OR 7.86, 95% CI 2.58-23.94), metastatic disease (OR 6.50, 95% CI 3.72-11.37), advanced-stage disease (OR 4.88, 95% CI 2.30-10.33), and mortality (OR 7.32, 95% CI 3.14-17.10). The association was stronger for disease-specific than all-cause mortality, although the subgroup difference was not statistically significant.
Por que isso importa
The germline RET M918T pathogenic variant was associated with adverse clinical outcomes compared with other germline RET pathogenic variants. However, heterogeneous comparator groups and residual confounding preclude causal interpretation.
Resumo publicado sob licença CC BY. A tradução para o português ainda não chegou a este estudo.
O estudo original
Clinical Outcomes of the Germline RET M918T Pathogenic Variant in Hereditary Medullary Thyroid Carcinoma: A Systematic Review and Meta-Analysis
Jurairat Jongthawin, Wanlaya Naowaratwattana, Jongkonnee Thanasai, Darunee Puangpronpitag, Hasaya Dokduang, Issarapong Phosuk, Wipavadee Daiponmak
Descritores MeSH
- Carcinoma, Neuroendocrine
- Multiple Endocrine Neoplasia Type 2a
- Proto-Oncogene Proteins c-ret
- Germ-Line Mutation
- Thyroid Neoplasms
- Carcinoma, Medullary
- Lymphatic Metastasis
- Humans
Veja também
Estudos relacionados
- Rare cases in two Chinese MEN2A families with RET C634Y germline mutation-a homozygous female patient and heterozygous identical twins: a systematic review of literature
- Gestão da síndrome de Cushing ectópica no carcinoma medular da tireoide: desde relatos de casos até revisão sistemática da literatura
- Selpercatinib versus multi-kinase inhibitors for advanced medullary thyroid cancer: A network meta-analysis of RET-targeted therapies
- Presentation of multiple endocrine neoplasia type 2A-associated ectopic cushing's syndrome: case report and a systematic review